Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of “Moderate Buy” by Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $53.50.

Several research analysts have recently commented on the company. Morgan Stanley boosted their price target on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Wednesday, June 17th. Cantor Fitzgerald initiated coverage on shares of Silence Therapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th.

Silence Therapeutics Stock Performance

NASDAQ SLN opened at $13.58 on Thursday. The company has a market cap of $641.52 million, a PE ratio of -10.61 and a beta of 1.39. The firm’s 50 day moving average price is $9.80 and its 200-day moving average price is $7.37. Silence Therapeutics has a 52-week low of $4.19 and a 52-week high of $17.58.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $1.13 million. Silence Therapeutics had a negative return on equity of 96.82% and a negative net margin of 8,943.86%. On average, analysts forecast that Silence Therapeutics will post -1.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its holdings in Silence Therapeutics by 18.1% in the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after acquiring an additional 1,698 shares in the last quarter. Boothbay Fund Management LLC raised its position in shares of Silence Therapeutics by 1.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after purchasing an additional 2,409 shares during the last quarter. Two Sigma Investments LP boosted its stake in Silence Therapeutics by 6.6% in the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after purchasing an additional 3,935 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in Silence Therapeutics by 26.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Silence Therapeutics by 65.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock worth $83,000 after purchasing an additional 5,421 shares during the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

More Silence Therapeutics News

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: Morgan Stanley reiterated a bullish view, maintaining an Overweight rating and issuing a Buy recommendation. The firm’s stance reinforces the positive analyst outlook for Silence’s siRNA pipeline and could support valuation. Morgan Stanley maintains Overweight rating on Silence Therapeutics
• Positive Sentiment: Several analyst roundups describe healthcare investors as bullish on SLN, while a separate report says the stock has a consensus rating of “Moderate Buy.” This indicates that Wall Street sentiment remains generally favorable despite recent volatility. Analysts Are Bullish on Top Healthcare Stocks
• Positive Sentiment: Silence discussed top-line results from the Phase II SANRECO trial of divesiran in polycythemia vera. The update keeps investor focus on a potentially important clinical asset, though the investment impact depends on the detailed efficacy and safety data. SANRECO Phase II Trial Slideshow
• Neutral Sentiment: The company priced an upsized underwritten public offering of 12,962,963 ADSs at $13.50 each, raising approximately $175 million before expenses. The proceeds improve funding for clinical programs, but the transaction also increases the share count. Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
• Negative Sentiment: The offering creates near-term dilution and may weigh on the stock, particularly with the deal priced close to the prevailing market level. Silence also recently reported a larger-than-expected quarterly loss, adding another concern for investors focused on cash burn and execution.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.